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Abstract
Aim of the study. The aim of this study was to evaluate granzyme B, perforin and FasL expression in peripheral blood mono-
nuclear cells (PBMCs) in lung cancer patients and in paraneoplastic neurological syndromes (PNS).
Clinical rationale for the study. Cellular immune response is activated as part of anti-tumour reaction of the malignancy-
-bearing host. Paraneoplastic neurological syndromes (PNS) are defined as indirect effects of cancer on the nervous system 
and are considered immune-mediated. Such stimulation of the immune system may limit the aggressiveness of cancer and 
the development of metastasis, and thereby improve survival. Granzyme B and perforin pathway, and Fas ligand (FasL) – Fas 
receptor interaction play an important role in cytotoxic response. 
Materials and Methods. Fifty-two patients were included in the study: 28 subjects with PNS and 24 subjects with lung cancer. 
PNS cases were diagnosed according to the Graus criteria. The presence of onconeural antibodies (anti-Hu/anti-Ri/anti-Yo/
anti-Ma/Ta/anti-CV2/anti-amphiphysin/anti-myelin/anti-neuroendothelium/anti-MAG/anti-GAD) was detected with indirect 
immunofluorescence and confirmed with Line Blotting. The expression of granzyme B, perforin and FasL was detected in PBMCs 
with ELISA. 
Results. PPBMC-FasL expression was increased in lung cancer compared to other patient groups. The granzyme to FasL ratio 
was significantly higher in lung cancer patients with peripheral than with central PNS involvement. In a multiple regression 
model, sex was an independent factor influencing PBMC expression of granzyme and perforin.
Conclusions. FasL expression in PBMCs is up-regulated in lung cancer patients. The interplay between granzyme B and FasL 
may be involved in the development of PNS at the level of the peripheral and the central nervous systems in different manners. 
Gender is associated with PBMC expression of granzyme B and perforin in lung cancer patients.
Clinical Implications. The novel findings that we report broaden the current knowledge on PNS pathomechanism, with aspects 
that have not been previously explored. Our findings provide a rationale for further exploration of the granzyme B/FasL pathway 
with regards to its potential diagnostic value. However, our study is preliminary and needs further research, especially in the 
context of the prognostic value of the proposed markers. 
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Introduction
Paraneoplastic neurological syndromes (PNS) are defined 
as the pathology of the nervous system observed in the course 
of a neoplastic disease, but unrelated to the direct effects of 
the tumour mass, such as infiltration, compression or me-
tastasis [1]. PNS diagnosis is based on detailed criteria that 
consider both the clinical manifestation and the presence of 
onconeural antibodies [1]. In general, PNS may affect central 
(encephalitis, limbic encephalitis, brain stem encephalitis, 
paraneoplastic cerebellar degeneration and opsoclonus/my-
oclonus) and peripheral (polyneuropathies) nervous systems, 
as well as the neuromuscular junction (myasthenic syndrome) 
and skeletal muscles (dermatomyositis). Among the most 
common malignancies associated with PNS are pulmonary 
pathologies, particularly small cell lung carcinoma (SCLC) 
[1, 2]. The clinical significance of PNS stems mainly from the 
fact that the diagnosis of the neurological pathology often 
precedes neoplastic manifestation. Patients affected with PNS 
undergo detailed oncological diagnostic procedures that fre-
quently result in detection of the tumour at an early stage of 
development. It has been suggested that neoplasms associated 
with these syndromes are less advanced, that metastases are 
rare, and that the overall outcome is favourable [3]. Cases of 
SCLC regression have been reported [4]. Some studies have 
suggested that in the course of PNS an effective anti-tumour 
response may develop [3]. Nonetheless, neither the origin of 
PNS nor the pathophysiological basis of a potentially more 
favourable outcome of the neoplastic disease is known, and 
this remains a hypothesis.
The prevailing view on the pathogenesis of PNS is based 
on the assertion that the immune system attacks the tumour 
and nervous tissue cells that share common antigens. The 
humoral response, however, has an unclear role in the patho-
mechanism of the disease. In some cases in animal models, 
the passive transfer of antibodies did not lead to nervous 
system pathology [5]. It appears, in turn, that lymphocytes 
withdrawn from blood samples of PNS patients were active 
against the same antigens as the antibodies used in diagnostic 
procedures e.g. onconeural antibodies. Mononuclear infiltrates 
have been observed in neuropathological studies of affected 
nervous tissue [6]. Immunohistopathologically it has been 
defined that these infiltrates consist mainly of lymphocytes 
CD3+ and CD8+ as well as less numerous CD4+ cells [7]. 
Cerebrospinal fluid analysis in PNS patients has revealed 
an increase of white blood cell count, including elevated T 
lymphocytes CD8+ and CD4+, natural killer cells (NK) and 
especially B cells [8]. Interestingly, patients afflicted with 
SCLC-associated anti-Hu syndrome with high pleocytosis 
have turned out to have a better overall survival rate [8]. The 
above-mentioned studies imply that a cell-mediated immune 
response takes part in the pathogenesis of PNS. One needs 
to recognise that the type of immune response may depend 
on the localisation of the antigens under attack. In classical 
paraneoplastic syndromes, where intracellular antigens (i.e. 
Hu, Ri, amphiphysin) are targeted by onconeural antibodies, 
the cellular response seems to play a key role. However, in cases 
of surface antigens (i.e. NMDA, GABA, AMPA), the humoral 
response, with antibody-mediated receptor dysfunction, may 
be of more significance. Apoptosis related to cytotoxic effect is 
mediated by Tumour Necrosis Factor (TNF) receptor, through 
FasL receptor (Fas) activation or by means of granzyme B 
containing granule excretion and perforin involvement. These 
molecules play a role in autoimmune disorders, but also in 
anti-tumour reaction. 
Granzymes are serine proteases that launch cell death in 
a number of mechanisms. When released to the extracellular 
space, they promote an inflammatory reaction [9]. The proapo-
ptotic function appears to be dependent on the presence of 
perforin that is a prerequisite to their entrance into the cell 
[10]. Granzymes may induce cytochrome c release, directly 
activate caspases or interfere with cell membrane integrity by 
cleavage of laminin B [11]. The most significant molecule in 
this class is granzyme B. The expression of both granzyme B 
and perforin turns out to play an important role in the reaction 
against tumour cells. Their concentration is closely related to 
survival in patients with neoplastic disease. 
Perforin is a Ca+2-dependent pore-forming protein with 
lytic activity. It leads to apoptosis through up-regulation of 
caspase-3 activity, release of apoptosis inducing factor (AIF), 
and cytochrome c from the mitochondria [12].
Fas Ligand (FasL) belongs to the TNF superfamily. It is 
a membrane protein that induces apoptosis by the specific 
receptor CD95 on a target cell. FasL is mainly expressed by 
cytotoxic lymphocytes and natural killer cells, but also by 
regulatory T lymphocytes. Fas activation induces two major 
mechanisms of cell death, depending on the cell type. It may 
either cause activation of mitochondria and release of cyto-
chrome C, or induce direct caspase cascade [13]. Fas/FasL 
interaction is part of a mechanism to prevent autoimmune 
reaction. It is the pathway to eliminate overactive or abundant 
lymphocytes [14]. Improper or insufficient expression of FasL 
has been proven to trigger autoimmune conditions in mice and 
in humans [15]. Fas is also involved in the interaction between 
the emerging tumour and the host immune system. On one 
hand, neoplastic cells escape lymphocyte cytotoxicity by low 
expression of Fas protein. On the other hand, tumour cells up-
-regulate FasL to eliminate immune cells that form a tumour
counterattack [16]. The expression of FasL has been revealed
at the surface of human lung cancer cells [17].
For the complex interactions between cytotoxic immune 
cells and target cells expressing well-characterised onconeural 
antibodies, see Figure 1.
Clinical rationale for the study 
In the present study, in order to determine the role of hu-
moral and cytotoxic reactions in lung cancer patients, serum 
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autoantibodies, as well as the expression of granzyme B, perfo-
rin and FasL in peripheral blood mononuclear cells (PBMC), 
were investigated in the context of PNS. The immunological 
pathomechanism of paraneoplastic syndrome remains poorly 
described. A better understanding in this area could contribute 
to new diagnostic and therapeutic developments. 
Material and methods
Fifty-two patients were recruited for the study: 28 subjects 
with suspected PNS who were hospitalised in the Depart-
ment of Neurology, Poznan University of Medical Sciences, 
and 24 subjects with lung cancer who were admitted to the 
Department of Pulmonology, Allergology and Respiratory 
Oncology, Poznan University of Medical Sciences. The study 
protocol was accepted by the Ethical Review Board of Poznan 
University of Medical Sciences, and each recruited partici-
pant gave written informed consent. PNS were diagnosed 
according to the 2004 Graus criteria [1]. The presence of 
well-defined onconeural antibodies (anti-Hu, anti-Ri, anti-
-Yo, anti-Ma/Ta, anti-CV2, anti-amphiphysin) was detected
by means of indirect immunofluorescence. If positive, it was
confirmed with a Line Blot (Euroimmun, Germany). Indirect 
immunofluorescence was also used for the detection of other 
antibodies: anti-myelin, anti-neuroendothelium, anti-myelin 
associated glycoprotein (anti-MAG) and anti-glutamic acid
decarboxylase (anti-GAD). The patterns of positive reactions 
were evaluated under a fluorescent microscope (EUROStar,
Zeiss). Each series of samples was preceded by testing the
positive and negative control sera.
PBMCs were isolated from heparinised blood samples 
by concentration gradient centrifugation (Ficoll Paque Plus, 
Healthcare) and frozen at -70ºC until further analysis. PBMC 
lysis was carried out with the use of lysis buffer containing 
a cocktail of proteinase inhibitors (Sigma-Aldrich, USA). In 
the next step, the expression of cytotoxicity markers: granzy-
me B (Abcam), perforin (Abcam), FasL (Enzo Life Sciences) 
was detected in the lysates with the use of ELISA. Protein 
concentration was estimated by means of the Lowry method 
[18]. The expression of cytotoxicity markers in PBMCs was 
expressed in pg/mg protein.
Statistical analysis was performed with the use of licensed 
MedCalc software version 12.3.0.0. First, the distribution 
of results was tested using the d’Agostino-Pearson test. The 
results with Gaussian distribution were expressed as means 
± standard deviation (SD) and analysed using the Student’s 
t-test. The results with a non-Gaussian distribution were ex-
pressed as median and interquartile range, and analysed using 
a non-parametric Mann-Whitney test.
Results
Having included all PNS and lung cancer patients, in the 
final study group there were 31 (60%) lung cancer patients, 
nine (17%) ovarian cancer, two (4%) prostate cancer, one 
(2%) with other malignancies, and nine (17%) cases without 
an identified malignancy. 
Of the 31 lung cancer patients, 24 were referred from the 
Department of Pulmonology, Allergology and Respiratory On-
cology, and the other seven were diagnosed in the Department 
of Neurology where they were admitted for suspected PNS.
Clinically, 20 (64.5%) patients manifested peripheral 
nervous system involvement (polyneuropathy/neuropathy, 
myasthenic syndrome, myopathy) and 11 (35.5%) had central 
nervous system involvement (cerebellar syndrome, motor 
neurone disease, extrapyramidal syndrome). 
Figure 1. Schematic presentation of the interactions between 
cytotoxic immune cell and target cell (neoplasm or normal cell 
expressing onconeural antigen): 1 – granzyme B from immune 
cell releases cytochrome C from target cell mitochondria; 2 – gran-
zyme B-mediated laminin cleavage; 3 – granzyme B-mediated 
caspase activation; 4 – perforin-mediated caspase activation; 
5 – perforin-mediated cytochrome C release from target cell mi-
tochondria; 6 –perforin-mediated AIF release; 7 – elimination of 
target cell by immune cell via Fas/FasL interaction; 8 – elimination 
of immune cell by FasL-expressing tumour cells. AIF – apoptosis 
inducing factor; cytC – cytochrome C; Ca – calcium; TNF – Tumour 
Necrosis Factor; FasL – Fas ligand
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In 15 (29%) patients, the presence of well-defined onco-
neural antibodies (anti-Hu, anti-amphiphysin, anti-Ri, anti-
-Yo, anti-Ma/Ta) was detected, and in 34 subjects (65%) other 
autoantibodies (anti-Tr, anti-MAG, anti-myelin) were found. 
In the lung cancer patients, eight (27%) had well-defined
onconeural antibodies (anti-Hu, anti-amphiphysin, anti-Ri,
anti-Yo, anti-Ma/Ta) and eight (27%) were seropositive for
other autoantibodies (anti-Tr, anti-MAG, anti-myelin).
Coexisting autoantibodies were detected in 17% of lung 
cancer patients. The coexistence profile included: anti-Hu 
with anti-Ma/Ta, anti-Hu with anti-amphiphysin, anti-Hu 
with anti-myelin, and anti-Ri with anti-myelin. In 17% of 
other neoplasms, the coexistence of onconeural antibodies 
was detected (anti-Ri with anti-amphiphysin and anti-Ma/Ta 
with anti-amphiphysin and with anti-Tr). 
The expression of FasL in PBMCs was increased in lung 
cancer patients compared to other groups of patients (Tab. 1). 
No differences in granzyme B expression in PBMCs were 
observed between the studied subgroups of patients (Tab. 2). 
The Granzyme B to FasL ratio differed (P = 0.0180) between 
lung cancer patients with peripheral (11,589; 166-58,242) and 
central PNS (73; 34-112). 
The expression of perforin in PBMCs of lung cancer 
patients with PNS was lower than in asymptomatic subjects 
(Tab. 3). And we observed a trend for down-regulation of 
perforin in lung cancer patients compared to other neoplasms 
(Tab. 3). 
In multiple regression analysis with gender, the presence 
of small cell lung cancer, onconeural antibodies and diagnosis 
of PNS included in the model, gender was an independent 
factor influencing PBMC expression of granzyme (b = 1,536; 
p = 0.0126) and perforin (b = 30,925; p = 0.0174). 
For the detailed characteristics of each individual patient 
with PNS in the study cohort, see supplementary Table 4.
Discussion
In the present study, lung cancer has been identified as 
a systemic malignancy that is associated with both the hu-
moral response directed against neural antigens, as well as 
Table 1. The expression of FasL in peripheral blood mononuclear cells
Studied group Studied subgroup FasL  
[pg/mg of protein]
p
Lung cancer patients (n = 31) Total (n = 31) 7.39 
0.02–11.87
p = 0.0171* 
PNS (n = 17) 0.11 
0.02–12.07
p = 0.9816
No PNS (n = 14) 8.55 
0.02–11.80
Well-defined antibodies (n = 8) 0.07 
0.03–4.87
p = 0.1043
Seronegative (n = 15) 11.38 
6.25–12.06
Other cancer patients (n = 12) Total (n = 12) 0.027 
0.01–5.73
p = 0.9955
PNS (n = 8) 0.05 
0.02–8.49
No PSN (n = 4) 0.05 
0.02–8.11
Well-defined antibodies (n = 5) 0.06 
0.02–11.60
p = 0.3209
Seronegative (n = 6) 0.03 
0.02–7.03
All patients (n = 52) PNS manifestation (n = 31) 0.06 
0.02–11.85
p = 0.7052
Without PNS symptoms (n = 21) 0.06 
0.02–9.25




1 vs 3: p = 0.7952 
2 vs 3: p = 0.9088 
1 vs 2: p = 0.5841 
(1+2) vs 3: p = 0.8146
2. Other autoantibodies (n = 15) 0.06 
0.02–10.56
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with changes of cytotoxicity markers expression on peripheral 
blood mononuclear cells. Onconeural antibodies are currently 
considered a diagnostic tool for the definitive recognition of 
PNS in general [1], and lung cancer patients in particular [2], 
but their role in PNS pathogenesis remains unclear. While 
for many years onconeural antibodies were not considered 
pathogenic [5], the discovery of clearly pathogenic antibodies 
directed against surface receptors (i.e. anti-NMDAR) has 
changed this perspective.
In this study, we observed well-defined onconeural an-
tibodies, and even their coexistence in lung cancer patients. 
However, the expression of granzyme B, perforin and FasL in 
PBMCs did not differ between seropositive and seronegative 
patients. Such an observation suggests an independence of 
the humoral and the cellular immune response in lung cancer 
patients. The cytotoxic effects in host-tumour interactions that 
lead to PNS play a particularly important role in the remote ef-
fects on the nervous system. Apoptosis and neurodegeneration 
triggered by mechanisms associated with cytotoxicity may be 
mediated by granzyme B, perforin and/or FasL. Mononuclear 
cells infiltrating dentate nucleus in paraneoplastic cerebellar 
degeneration express granzyme B [7]. 
Recently, an immunopathological study on autoimmune 
encephalitis, including cases of paraneoplastic origin, sho-
wed a higher CD8/CD3 ratio and a substantial collocation 
of neurons and T lymphocytes expressing granzyme B [19]. 
Based on the observed differences between immune reactions 
against intracellular antigens, Bien et al. suggested the crucial 
role of cytotoxic reaction mediated by T lymphocytes in cases 
where response against intracellular antigens was developed, 
while in autoimmune reaction against surface antigens the 
involvement of antibodies and complement takes place [19]. 
Cell specificity analysis revealed the existence of cytotoxic T 
lymphocytes aggressive towards HuD protein [20], which is 
an antigen expressed on both small cell lung cancer cells and 
neurons. One of the most common PNSs is Hu-syndrome 
Table 2. The expression of Granzyme B in peripheral blood mononuclear cells
Studied group Studied subgroup Granzyme B  
[pg/mg of protein]
p
Lung cancer patients (n = 31) Total (n = 31) 1,839 
1,150–3,213
p = 0.8965
PNS (n = 17) 1,824 
1,265–2,640
p = 0.7297
No PNS (n = 14) 1,958 
1,001–3,740
Well-defined antibodies (n = 8) 1,580 
930–2,640
p = 0.8430
Seronegative (n = 15) 1,708 
1,177–2,184
Other cancer patients (n=12) Total (n = 12) 1,961 
1,432–2,576
p = 0.8124
PNS (n = 8) 1,959 
1,284–2,741
No PNS (n = 4) 1,895 
1,332–2,628
Well-defined antibodies (n = 5) 1,936 
1,302–2,766
p = 0.8344
Seronegative (n = 6) 1,961 
1,268–2,716
All patients (n=52) PNS manifestation (n = 31) 1,895 
1,304–2,606
p = 0.8481
Without PNS symptoms (n = 21) 1,958 
1,116–2,922
 Antibodies 1. Well-defined onconeural 
antibodies (n = 15)
1,936 
1,268–2,594
1 vs 2: p = 0.6639 
1 vs 3: p = 0.7328 
2 vs 3: p = 0.5929 
(1+2) vs 3: p = 0.9299
2. Other autoantibodies (n = 15) 1,942 
1,167–3,612
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Table 3. The expression of Perforin in peripheral blood mononuclear cells
Studied group Studied subgroup Perforin 
[pg/mg of protein]
p
Lung cancer patients (n = 31) total (n = 31) 13365 
3634–38240
p = 0.0606
PNS (n = 17) 12633 
3968–38949
p = 0.0404* 
no PNS (n = 14) 23480 
3639–35426
well-defined antibodies (n = 8) 14097 
9608–38578
p = 0.9788
seronegative (n = 15) 11138 
3220–37822
Other cancer patients (n = 12) total (n = 12) 29663 
20336–35881
p = 0.7311
PNS (n = 8) 27307 
16753–35664
no PNS (n = 4) 23135 
11625–35893
well-defined antibodies (n = 5) 24986 
6997–35447
p = 0.7490
seronegative (n = 6) 26587 
12633–35881
All patients (n = 52) PNS manifestation (n = 31) 22707 
7592–33451
p = 0.4669
without PNS symptoms (n = 21) 24105 
11078–37065
 Antibodies 1. well-defined onconeural 
antibodies (n = 15)
26620 
12633–33143
1 vs 3: p =  0.7952 
2 vs 3: p = 0.7892 
1 vs 2: p = 0.9128 
(1+2) vs 3: p = 0.7491
2. other autoantibodies (n = 15) 23480 
8925–39325
3. seronegative (n = 26) 21736 
4754–35012
*Statistically significant difference
that coexists with SLCC and typically manifests as an en-
cephalomyelitis or sensory neuronopathy associated with 
anti-Hu antibodies. Tumour infiltrating lymphocytes have 
also been shown to react specifically with HuD antigen [21]. 
However, in Hu-syndrome, two distinct functional forms of 
cytotoxic lymphocytes have been described. It appears that in 
the acute phase of paraneoplastic syndrome, specific immune 
cells release type 1 cytokines (tumour necrosis factor-alpha, 
interleukin-6, interleukin-17), which promote a cell-mediated 
cytotoxic response. On the other hand, in the chronic phase 
of the disease, lymphocytes instead produce type 2 cytokines 
(interleukin-4, interleukin-5, interleukin-13) that abate an 
anti-tumour cytotoxic reaction. This functional transition 
was thought to be related to cytokines released by the SCLC 
[22]. In experimental conditions, paraneoplastic cerebellar 
degeneration was associated with interplay between tumo-
ur necrosis factor-alpha and macrophage chemoattractant 
protein-1 [23]. Thus, it can be hypothesised that the initially 
aggressive cell-mediated immune response that triggered 
paraneoplastic syndrome was distorted by secretions released 
by the growing tumour.
Our study is in concordance with the above-mentioned 
observations, because in our cohort of lung cancer patients 
we have found both antibodies against intracellular antigens 
(anti-Hu, anti-Ri, anti-amphiphysin, anti-Yo, anti-Ma/Ta) and 
up-regulated markers of cytotoxicity in PBMCs (namely FasL). 
However, in our cohort the spectrum of cytotoxicity markers 
differs from some other studies. Bernal et al. (2002) did not 
find Fas and FasL-positive cells in the infiltrates in anti-Hu-
-associated paraneoplastic encephalomyelitis [24]. Similarly,
Tüzün et al. (2009) observed only rare cells with granzyme B, 
perforin and Fas/Fas ligand expression in ovarian teratoma pa-
tients with NMDA-encephalitis [25]. One possible explanation 
for such discrepancies could be that the patient groups differed 
in terms of the underlying malignancy, clinical manifestation, 
and associated antibodies. This may confirm the hypothesis
of different pathomechanisms involved in PNS depending on 
target antigens in autoimmune response.
207www.journals.viamedica.pl/neurologia_neurochirurgia_polska
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Interestingly, we confirmed that gender has an influence on 
PBMC expression of granzyme B and perforin in lung cancer 
patients. This observation requires further investigation and 
confirmation on a larger sample.
We expected to find increased levels of immune cytotoxi-
city markers in lung cancer patients with PNS, compared to 
those without neurological involvement. Neuronal destruction 
observed in the course of paraneoplastic syndromes could be 
driven by direct cytotoxic effects of immune cells activated 
in response to the tumour. In this case, the overexpression of 
immune cell-FasL, which enhances target (nervous system) 
cell elimination via interaction with Fas, and overexpression 
of membranolytic proteins (granzyme B and perforin), could 
reflect the role of cellular response in PNS pathophysiology. 
We did not manage to confirm this hypothesis. However, we 
must acknowledge that our study is limited by a relatively 
small sample size and the marked heterogeneity of our study 
cohort. It would be worthwhile to assess and compare cytoto-
xicity markers expression in larger and more focused cohorts, 
for example between cohorts with different antibody profiles 
(ant-Hu, anti-amphiphysin etc.) or larger samples of different 
malignancies.
It should be emphasised that in nine patients who were 
included in the study cohort, no malignancies were identified. 
However, according to the 2004 Graus criteria [1], when ma-
lignancy is not detected, it is still possible to diagnose a para-
neoplastic syndrome. In fact, for definitive PNS, a neurological 
syndrome (classical or not) with well characterised onconeural 
antibodies (anti-Hu, Yo, CV2, Ri, Ma2, or amphiphysin) and 
no cancer, is considered paraneoplastic. For possible PNS, 
the criteria name two situations: a classical syndrome with no 
onconeural antibodies, no cancer, but at high risk of having 
an underlying tumour; or a neurological syndrome (classical 
or not) with partially characterised onconeural antibodies 
and no cancer.
In summary, ours is a preliminary study showing that lung 
cancer patients manifested a broader spectrum of coexisting 
autoantibodies than other patients with PNS in our cohort, 
namely patients with other malignancies and without an iden-
tified malignancy. FasL expression in PBMC is up-regulated 
in lung cancer patients. The interplay between granzyme B 
and FasL may be involved in the development of PNS at the 
level of the peripheral and central nervous systems in different 
manners.
Clinical implications and future directions 
The novel findings that we report broaden the current 
knowledge regarding PNS pathomechanism with aspects 
that have not been previously explored. However, our study 
is preliminary and needs further research. Firstly, it would be 
valuable to verify protein expression by other methods, i.e. 
PCR or flow cytometry. Secondly, measurement of protein 
levels in particular lymphocytic populations, and not just in 
total PBMCs, could aid in the interpretation of the results. 
Importantly, in this study we did not include data with regards 
to treatment and response to therapy, so we could not analyse 
the prognostic aspect of our findings. 
However, the purpose of this article was to provide an 
insight into the pathophysiology of PNS and to assess the 
potential diagnostic value of the proposed markers. For future 
studies, it would be interesting to investigate the prognostic 
value of the proposed markers as well. 
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